BCL11A and breast carcinoma: Recently, Choi et al. found that inhibition of BCL11A and HDAC1/2 can reprogram basal‐like breast cancer cells into luminal A breast cancer cells, which induces sensitivity to endocrine therapy.[8] They constructed a Boolean network model that can represent basal and luminal A breast cancer cells with two input nodes, EGF and Estrogen.